Quibim, a Valencia-based HealthTech firm innovating using imaging biomarkers for precision medication, introduced in the present day the shut of its €47.9 million Sequence A financing so as set up US presence.
The financing was led by Asabys (by its fund Sabadell Asabys II) and Buenavista Fairness Companions (by the BHG I fund, created in partnership with Columbus Enterprise Companions), and joined by GoHub Ventures and UI Investissement as new traders. It was additionally joined by present traders, Amadeus Capital Companions, APEX Ventures, Partech, Adara Ventures, Leadwind (KFund’s early development fund), Tony Fadell’s Construct Collective, and particular person investor Dr. Jonathan Milner, founding father of Abcam plc.
“Quibim’s mission is to show imaging right into a catalyst for precision well being, and we’re deeply grateful to each our new and present traders for his or her help,” mentioned Dr Ángel Alberich-Bayarri, CEO and Co-founder of Quibim. “Our international growth into the U.S. is a crucial milestone as we work with pharmaceutical leaders and healthcare suppliers to unlock the ability of imaging to revolutionise diagnostics and enhance affected person outcomes.”
Based in 2012 by Dr Ángel Alberich-Bayarri and Luis Martí Bonmatí, Quibim is devoted to the mission of unlocking a whole, non-invasive understanding of each tissue level within the human physique, at any second in time. To attain this, the corporate develops foundational AI fashions utilized to imaging that extract actionable insights from MRI, CT, and PET scans. These insights allow exact characterisation of phenotypes and prediction of outcomes in areas similar to oncology, immunology, neurology and metabolic problems.
Quibim says that is the pathway towards attaining human digital twins, dynamic fashions that not solely replicate and permit well being monitoring but in addition improve affected person stratification, enhance the success charges of drug growth packages, and allow therapy testing earlier than utility.
Right this moment, the corporate is constructing digital twins on the organ and lesion stage, exemplified by options like QP-Mind, QP-Prostate, and QP-Liver.
Nevertheless, as the amount of whole-body scans and associated imaging information continues to develop within the coming years, Quibim goals for his or her fashions to ultimately analyse your entire physique.
With over 170 installations worldwide, together with in Mass Basic Brigham and Stanford, and regulatory clearances throughout the US, EU, UK, Quibim’s know-how appears to be like to bridgethe hole between analysis, scientific apply, and drug growth.
Final yr, Philips introduced a world partnership with Quibim to combine its AI fashions into MR scanners, whereas the corporate additionally secured strategic alliances with main biopharma giants similar to Merck KGaA and Novartis.
“Asabys is thrilled to help Quibim in remodeling the imaging diagnostics area,” mentioned Guillem Masferrer, Accomplice at Asabys Companions. “Their skill to mix AI with imaging biomarker discovery addresses crucial unmet wants in oncology, neurology, and past. We’re assured that Quibim’s progressive options could have a profound impression on international healthcare.”
Quibim’s product portfolio consists of:
- QP-Prostate®: the corporate’s flagship product is designed to reinforce prostate most cancers detection by an industry-leading AI-powered lesion detection.
- QP-Mind®: AI-based early-stage neurological illness quantification software program for quantification of early mind atrophy and lesions.
- QP-Liver®: automated AI device for MR analysis of diffuse liver ailments by correct quantification of tissue fats and iron ranges.
- QP-Insights®: A platform to handle, retailer and analyse multi-omics information in scientific trials and real-world information research. Based on Quibim, QP-Insights is the platform managing the biggest imaging datasets on the earth, accounting for greater than 100 million medical photographs.
With the sequence A financing, Quibim will set up a powerful U.S. presence, constructing on its success in Europe, by strategic collaborations with hospitals and pharmaceutical corporations.
“Quibim’s know-how exemplifies the following wave of precision medication,” mentioned José Mesa, Accomplice at Columbus and Buenavista’s consultant on the Board. “Their spectacular monitor report with international pharmaceutical partnerships, together with partnerships with corporations similar to Merck KGaA and Philips, exemplify Quibim’s position in remodeling imaging information into worthwhile predictions for scientific trials and therapy planning. We count on that as Quibim develops its pipeline of companion diagnostic instruments, we are going to see large momentum for its know-how and merchandise.”
“The foundational analysis carried out by Quibim’s workforce has not solely knowledgeable {industry} requirements, but in addition led to the corporate pioneering an strategy to combining radiomics and deep studying that’s now a regular of its personal,” mentioned Pierre Socha, Accomplice at Amadeus Capital Companions. “This platform strategy was novel on the time of our first funding and proved to be the appropriate technique for fast scale-up.”
